4results about How to "Concentration dependent" patented technology

The application discloses an egg yolk antibody against Nocardiosis and a preparation method and application thereof, and relates to the technical field of biological medicines. A light chain sequence of the egg yolk antibody comprises a sequence shown in SEQ ID NO. 1, and a heavy chain sequence comprises a sequence shown in SEQ ID NO. 2. The application expands culture of pathogenic bacteria Nocardia, prepares an inactivated bacterin vaccine, and immunizes hens, so that the hens produce egg yolk antibodies against Nocardia through an immune response. After immunization, the application collects eggs, extracts the egg yolk antibodies against Nocardiosis from egg yolk by using a water dilution method. It is verified that the egg yolk antibodies have a strong binding capacity with Nocardia, can effectively inhibit Nocardia, and the titer can reach 1:64000 at the highest.

The invention belongs to the field of biological medicines, and discloses application of 7-galloyl tericolor flavane in preparation of antibacterial medicines. The inventor finds that the 7-galloyl tetra-chromatin inhibits the growth of MRSA for the first time, the MIC and MBC of the 7-galloyl tetra-chromatin to the MRSA are 100 mu g / mL and 400 mu g / mL respectively, and the antibacterial effect of the 7-galloyl tetra-chromatin is obviously superior to that of the disclosed pithecellobium clypearia crude extract (such as 800 mu g / mL of aqueous extract MIC and 400 mu g / mL of alcohol extract MIC). In addition, the 7-GTDF can inhibit the growth speed of the strain at the sub-inhibitory concentration and prolong the time for the strain to reach a logarithmic phase and a stationary phase, and the effect has concentration dependence. The 7-GTDF has a killing effect on MRSA under a certain concentration, and has time and concentration dependence. A crystal violet staining result shows that the formation of an MRSA biological membrane can be effectively inhibited under the sub-inhibitory concentration, and the inhibition effect is enhanced along with the increase of the drug concentration. The 7-GTDF is expected to be developed into a medicine for resisting the methicillin-resistant staphylococcus aureus.

The invention belongs to the technical field of biological medicines, and discloses application of tetrandrine in preparation of a medicine for inhibiting human papilloma virus infection. The invention discloses an application of tetrandrine or a pharmaceutically acceptable salt thereof in preparation of an anti-HPV (human papillomavirus) infection medicine. The application of the traditional Chinese medicine monomer component tetrandrine or the pharmaceutically acceptable salt thereof in preparation of the anti-HPV (especially high-risk HPV16) infection medicine is found and verified for the first time, the inhibition effect of the tetrandrine or the pharmaceutically acceptable salt thereof has the characteristic of concentration dependence, and a brand new technical path is opened up for research and development of the anti-HPV medicine.

This invention belongs to the field of pharmaceutical technology and discloses the inhibitory effects and mechanisms of action of sclerotinib on lung cancer cells, cervical cancer cells, and ovarian cancer cells. Compared with the currently available broad-spectrum antitumor drug fluorouracil, sclerotinib exhibits superior antitumor properties. In-depth research revealed that sclerotinib acts on the novel protein STAT3 in cancer treatment, inhibiting STAT3 phosphorylation and preventing phosphonate-modified protein dimers from entering the cell nucleus to initiate transcription. Furthermore, sclerotinib inhibits the downstream anti-apoptotic protein BCL-2 of STAT3, synergistically inhibiting tumor cell proliferation. In this study, based on the half-maximal inhibitory concentration (IC50) results of sclerotinib against lung cancer cells A549, cervical cancer cells HeLa, and ovarian cancer cells A2780, we directly verified the anticancer target of sclerotinib through experiments, elucidated its anticancer mechanism, and provided theoretical and experimental basis for its entry into preclinical and clinical trials.